Joshua Klopper
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 28 | 2026 | 380 | 3.250 |
Why?
| | Thyroid Nodule | 10 | 2026 | 67 | 1.650 |
Why?
| | Tetrahydronaphthalenes | 3 | 2015 | 34 | 0.770 |
Why?
| | Carcinoma, Papillary | 6 | 2016 | 83 | 0.730 |
Why?
| | Thiazolidinediones | 4 | 2013 | 142 | 0.610 |
Why?
| | Retinoids | 3 | 2009 | 34 | 0.550 |
Why?
| | Promoter Regions, Genetic | 3 | 2026 | 1242 | 0.480 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2015 | 43 | 0.450 |
Why?
| | Retinoid X Receptors | 4 | 2010 | 42 | 0.430 |
Why?
| | Anticarcinogenic Agents | 1 | 2015 | 63 | 0.420 |
Why?
| | Telomerase | 3 | 2026 | 252 | 0.420 |
Why?
| | Mutation | 7 | 2026 | 4093 | 0.420 |
Why?
| | Thyroidectomy | 4 | 2026 | 97 | 0.420 |
Why?
| | PPAR gamma | 4 | 2013 | 182 | 0.400 |
Why?
| | Biopsy, Fine-Needle | 10 | 2026 | 79 | 0.370 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 19 | 0.330 |
Why?
| | Triiodothyronine | 1 | 2011 | 55 | 0.330 |
Why?
| | Carcinoma | 2 | 2015 | 225 | 0.330 |
Why?
| | Thyroxine | 1 | 2011 | 67 | 0.330 |
Why?
| | Hypothyroidism | 1 | 2011 | 68 | 0.320 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 54 | 0.310 |
Why?
| | Calcitriol | 1 | 2010 | 59 | 0.310 |
Why?
| | Pathology, Molecular | 2 | 2026 | 28 | 0.280 |
Why?
| | GTP Phosphohydrolases | 2 | 2026 | 95 | 0.280 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 213 | 0.250 |
Why?
| | Gene Expression Profiling | 6 | 2026 | 1792 | 0.250 |
Why?
| | Thyroid Gland | 3 | 2024 | 93 | 0.230 |
Why?
| | Thyroid Diseases | 1 | 2026 | 45 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 1998 | 0.220 |
Why?
| | Retinoid X Receptor gamma | 1 | 2004 | 5 | 0.210 |
Why?
| | Biomarkers, Tumor | 2 | 2026 | 1339 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2026 | 457 | 0.190 |
Why?
| | Melanoma | 2 | 2009 | 765 | 0.190 |
Why?
| | Membrane Proteins | 2 | 2026 | 1130 | 0.190 |
Why?
| | Liver | 1 | 2011 | 1864 | 0.180 |
Why?
| | Carrier Proteins | 1 | 2026 | 728 | 0.180 |
Why?
| | Cell Line, Tumor | 6 | 2010 | 3545 | 0.170 |
Why?
| | Decision Support Techniques | 2 | 2015 | 478 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2026 | 2791 | 0.150 |
Why?
| | Antineoplastic Agents | 3 | 2008 | 2219 | 0.150 |
Why?
| | Humans | 36 | 2026 | 146342 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2012 | 415 | 0.130 |
Why?
| | DNA Mutational Analysis | 2 | 2024 | 410 | 0.110 |
Why?
| | Female | 19 | 2026 | 79499 | 0.110 |
Why?
| | Hypocalcemia | 1 | 2015 | 40 | 0.110 |
Why?
| | Appendicitis | 1 | 2017 | 151 | 0.110 |
Why?
| | Lymph Nodes | 2 | 2015 | 511 | 0.110 |
Why?
| | Retrospective Studies | 10 | 2026 | 17438 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2009 | 930 | 0.110 |
Why?
| | Middle Aged | 12 | 2026 | 36619 | 0.110 |
Why?
| | Ligands | 2 | 2009 | 678 | 0.110 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 56 | 0.100 |
Why?
| | Access to Information | 1 | 2014 | 46 | 0.100 |
Why?
| | Receptors, Retinoic Acid | 2 | 2004 | 44 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 893 | 0.100 |
Why?
| | Medical Record Linkage | 1 | 2014 | 68 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 200 | 0.090 |
Why?
| | Transcriptome | 2 | 2024 | 1068 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2024 | 1998 | 0.090 |
Why?
| | Aged | 7 | 2026 | 26432 | 0.090 |
Why?
| | Population Surveillance | 1 | 2016 | 481 | 0.090 |
Why?
| | Lymphatic Metastasis | 4 | 2015 | 335 | 0.090 |
Why?
| | Adult | 10 | 2026 | 41087 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 279 | 0.090 |
Why?
| | Male | 14 | 2026 | 73396 | 0.090 |
Why?
| | Delivery of Health Care | 2 | 2016 | 947 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2016 | 594 | 0.080 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.080 |
Why?
| | Benzoates | 2 | 2009 | 48 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1591 | 0.080 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 14 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2009 | 2502 | 0.080 |
Why?
| | Steroid Hydroxylases | 1 | 2010 | 20 | 0.080 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2010 | 16 | 0.080 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 18 | 0.080 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2012 | 268 | 0.080 |
Why?
| | Paclitaxel | 2 | 2013 | 260 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1181 | 0.070 |
Why?
| | Genomics | 2 | 2026 | 853 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2921 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2010 | 209 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1493 | 0.070 |
Why?
| | Patient Care Team | 1 | 2014 | 701 | 0.070 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2009 | 104 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 160 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 612 | 0.070 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 139 | 0.060 |
Why?
| | Cell Survival | 1 | 2010 | 1105 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2123 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 402 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 633 | 0.060 |
Why?
| | Mice, Nude | 1 | 2008 | 668 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2014 | 1210 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 371 | 0.060 |
Why?
| | Prognosis | 3 | 2026 | 4351 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 752 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 104 | 0.060 |
Why?
| | Registries | 1 | 2015 | 2400 | 0.060 |
Why?
| | Milk, Human | 1 | 1988 | 176 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 974 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 444 | 0.060 |
Why?
| | Prospective Studies | 3 | 2026 | 8123 | 0.060 |
Why?
| | PAX8 Transcription Factor | 1 | 2024 | 5 | 0.050 |
Why?
| | South Africa | 1 | 2026 | 262 | 0.050 |
Why?
| | ROC Curve | 2 | 2017 | 617 | 0.050 |
Why?
| | Young Adult | 4 | 2026 | 14330 | 0.050 |
Why?
| | Luciferases | 1 | 2004 | 153 | 0.050 |
Why?
| | Immunoprecipitation | 1 | 2004 | 150 | 0.050 |
Why?
| | Adenoma | 1 | 2026 | 210 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2015 | 11821 | 0.050 |
Why?
| | Genetic Testing | 1 | 2026 | 492 | 0.050 |
Why?
| | Gene Frequency | 1 | 2024 | 496 | 0.050 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2024 | 231 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 3034 | 0.050 |
Why?
| | Mice | 3 | 2009 | 18297 | 0.040 |
Why?
| | Risk Assessment | 2 | 2026 | 3712 | 0.040 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2022 | 38 | 0.040 |
Why?
| | Blotting, Western | 1 | 2004 | 1177 | 0.040 |
Why?
| | HIV Infections | 1 | 2017 | 3215 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8391 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2026 | 2113 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2240 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3416 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 2012 | 504 | 0.040 |
Why?
| | Gene Expression | 1 | 2004 | 1463 | 0.040 |
Why?
| | Apoptosis | 2 | 2004 | 2439 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2014 | 1488 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2017 | 56 | 0.030 |
Why?
| | Animals | 3 | 2009 | 38107 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1503 | 0.030 |
Why?
| | RNA | 1 | 2022 | 926 | 0.030 |
Why?
| | Transcription Factors | 1 | 2004 | 1730 | 0.030 |
Why?
| | Neck | 1 | 2015 | 107 | 0.030 |
Why?
| | Health Plan Implementation | 1 | 2016 | 143 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 70 | 0.030 |
Why?
| | Perioperative Period | 1 | 2014 | 69 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 6077 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1038 | 0.030 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2013 | 15 | 0.030 |
Why?
| | Expert Testimony | 1 | 2014 | 43 | 0.030 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2013 | 37 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 640 | 0.020 |
Why?
| | Adolescent | 2 | 2026 | 22557 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2014 | 267 | 0.020 |
Why?
| | Child | 2 | 2026 | 22693 | 0.020 |
Why?
| | Research | 1 | 2015 | 421 | 0.020 |
Why?
| | Adiponectin | 1 | 2013 | 243 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 471 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 645 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2012 | 324 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1133 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2010 | 79 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2010 | 181 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1888 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 462 | 0.020 |
Why?
| | Internet | 1 | 2014 | 660 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1665 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1712 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 702 | 0.020 |
Why?
| | Patient Participation | 1 | 2012 | 457 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1163 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1137 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2936 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3647 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1432 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2010 | 416 | 0.020 |
Why?
| | United States | 2 | 2016 | 16136 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 1982 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2006 | 8 | 0.010 |
Why?
| | Chromans | 1 | 2006 | 25 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 259 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1988 | 279 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1160 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2009 | 1135 | 0.010 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 239 | 0.010 |
Why?
| | Breast Feeding | 1 | 1988 | 447 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1150 | 0.010 |
Why?
| | Quality of Life | 1 | 2016 | 3200 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2004 | 391 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 736 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 882 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11913 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1849 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 595 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2009 | 5439 | 0.010 |
Why?
|
|
Klopper's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|